Ricardo Ahrens, Kyra Ahrens, Maximilian Al-Bazaz, Lisa Leypoldt, Carsten Bokemeyer, Winfried Alsdorf, Katja Weisel
{"title":"A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma.","authors":"Ricardo Ahrens, Kyra Ahrens, Maximilian Al-Bazaz, Lisa Leypoldt, Carsten Bokemeyer, Winfried Alsdorf, Katja Weisel","doi":"10.1038/s41408-026-01616-6","DOIUrl":"https://doi.org/10.1038/s41408-026-01616-6","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Doris K Hansen, Danai Dima, Hira Mian, Jakob Devos, Ruta Brazauskas, Temitope Oloyede, Aimaz Afrough, Nausheen Ahmed, Larry D Anderson, Rahul Banerjee, Jesus G Berdeja, Aram Bidikian, Binod Dhakal, Ajoy Dias, Yvonne Efebera, Muhammad Salman Faisal, Lohith Gowda, Hamza Hashmi, Abu-Sayeef Mirza, Meera Mohan, Ravi Narra, Ashley E Rosko, Mark Schroeder, Taiga Nishihori, Heather Landau, Saad Usmani, Marcelo C Pasquini, Othman S Akhtar, Surbhi Sidana, Krina K Patel
{"title":"Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.","authors":"Doris K Hansen, Danai Dima, Hira Mian, Jakob Devos, Ruta Brazauskas, Temitope Oloyede, Aimaz Afrough, Nausheen Ahmed, Larry D Anderson, Rahul Banerjee, Jesus G Berdeja, Aram Bidikian, Binod Dhakal, Ajoy Dias, Yvonne Efebera, Muhammad Salman Faisal, Lohith Gowda, Hamza Hashmi, Abu-Sayeef Mirza, Meera Mohan, Ravi Narra, Ashley E Rosko, Mark Schroeder, Taiga Nishihori, Heather Landau, Saad Usmani, Marcelo C Pasquini, Othman S Akhtar, Surbhi Sidana, Krina K Patel","doi":"10.1038/s41408-026-01605-9","DOIUrl":"10.1038/s41408-026-01605-9","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13530125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Samer Al Hadidi, Eric Chinaeke, Jinghua He, Helen Pai, Agne Paner-Straseviciute, Ibrahim Saber, Jessica Fowler, Tonya Le Blanc, Niodita Gupta-Werner, Xinke Zhang, Shuchita Kaila
{"title":"Infection burden among patients with triple-class–exposed RRMM receiving non–T-cell–redirecting therapies: a US claims study","authors":"Samer Al Hadidi, Eric Chinaeke, Jinghua He, Helen Pai, Agne Paner-Straseviciute, Ibrahim Saber, Jessica Fowler, Tonya Le Blanc, Niodita Gupta-Werner, Xinke Zhang, Shuchita Kaila","doi":"10.1038/s41408-026-01614-8","DOIUrl":"https://doi.org/10.1038/s41408-026-01614-8","url":null,"abstract":"Triple-class–exposed (TCE) relapsed/refractory multiple myeloma (RRMM) is associated with cumulative immunosuppression and heightened infection risk. In this longitudinal, retrospective, observational study, US claims data from the Komodo Healthcare Map (KHM; n = 2702; median follow-up, 9.5 months) and the All-Payer Claims Data (APCD; n = 1755; median follow-up, 14.9 months) were used to assess infection burden in patients with TCE RRMM receiving non-bispecific antibody therapies after ≥4 prior lines of therapy (LOTs). The study period was from 1/1/2016 through 10/31/2024. Median (range) index LOT number was 5 (5–5; KHM) and 5 (5–6; APCD); median (interquartile range) age was 67.0 (60–75; KHM) and 71.0 (64–77; APCD) years. Across datasets, the weighted average rate for any infection was 63.5% (95% confidence interval [CI], 61.2–65.8), with the most common infection type being bacterial (58.2%), then viral (27.4%) and fungal (8.2%). Severe infections occurred in 46.1% of patients (95% CI, 44.1–48.1). Cumulative infection rates increased from 49.5 (26 weeks) to 66.4% (52 weeks); cumulative severe infection rates increased from 31.5 to 44.9%, respectively. These findings demonstrate substantial real-world infection burden in heavily pretreated patients with TCE RRMM receiving non-bispecific antibody and non–CAR-T therapies, underscoring the need for infection prophylaxis and supportive care.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"38 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148853489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meera Mohan, Anushareddy Muddasani, Hayder Alkhalisy, Lisa Rein, Jean Esselman, Binod Dhakal, Anita D’Souza, Sabarinath Venniyil Radhakrishnan, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Aniko Szabo, Carolina Schinke
{"title":"Immune effector cell associated hematotoxicity (ICAHT) with BCMA CAR T cell therapy in the earlier lines","authors":"Meera Mohan, Anushareddy Muddasani, Hayder Alkhalisy, Lisa Rein, Jean Esselman, Binod Dhakal, Anita D’Souza, Sabarinath Venniyil Radhakrishnan, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Aniko Szabo, Carolina Schinke","doi":"10.1038/s41408-026-01611-x","DOIUrl":"https://doi.org/10.1038/s41408-026-01611-x","url":null,"abstract":"B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy is highly effective in relapsed/refractory multiple myeloma (MM), but adverse effects such as immune effector cell–associated hematotoxicity (ICAHT) remain a challenging early and long-term toxicity. Most reports on ICAHT originate from CAR T-cell therapies in late-stage MM, with limited data from earlier-line treatment. We conducted a multi-institutional retrospective study of 245 MM patients treated with BCMA CAR T, comparing ICAHT between early-line [early CAR T] (1–3 prior lines; n = 69) and late-line [late CAR T] (≥4 prior lines; n = 176) cohorts. Cytopenias (neutropenia ≤1000/µL, thrombocytopenia ≤50,000/µL, anemia ≤9 g/dL) were assessed at day 21 (D + 21), 3, and 6 months post-CAR T-cell infusion. At D + 21, ICAHT was less frequent with early CAR T versus late CAR T (39% vs 62%; p = 0.002), driven largely by lower thrombocytopenia (17% vs 39%; p = 0.001). At 3 months, ICAHT remained more common with late CAR T (30% vs 12%; p = 0.004), but by 6 months, rates converged (8.9% vs 18%; p = 0.126). Blood counts among patients with ICAHT at D + 21 often remained inferior at 3 and 6 months despite stem cell boosts. ICAHT at D + 21 independently predicted worse overall survival (HR 3.12; p = 0.022). Early-line CAR T-cell therapy was associated with superior 12-month PFS (87.8% vs 65.4%) and OS (96.2% vs 85.9%). These real-world data show that ICAHT occurs even with earlier-line BCMA CAR T-cell therapy, though less severe, and underscore the prognostic importance of early post-infusion cytopenias.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"25 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148769228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarah Matarasso Greenfeld, Rakan Okde, Mark Sorin, Olivia Benguigui, Joseph Tuscano, Maria Sannikova, Eugene Nikitin, Lorenzo Falchi, Sarit Assouline
{"title":"Lenalidomide and rituximab for relapsed/refractory follicular lymphoma: a systematic review and meta-analysis","authors":"Sarah Matarasso Greenfeld, Rakan Okde, Mark Sorin, Olivia Benguigui, Joseph Tuscano, Maria Sannikova, Eugene Nikitin, Lorenzo Falchi, Sarit Assouline","doi":"10.1038/s41408-026-01608-6","DOIUrl":"https://doi.org/10.1038/s41408-026-01608-6","url":null,"abstract":"Lenalidomide (len) and rituximab (R2) is standard second-line therapy for follicular lymphoma (FL), and the backbone and comparator for several new therapies. This systematic review and meta-analysis of R2 or len-anti-CD20 monoclonal antibodies aims to clarify efficacy across trials, and to evaluate the benefit of triplet therapies including R2. Across 24 treatment arms involving 2245 patients, 63% received R2 or len-anti-CD20 and 37% received it with an additional agent. For R2/len-anti-CD20, the overall response rate (ORR) was 75.9% (95% CI 72.1–79.3, p = 0.0092; I2 = 53.5%), and complete response rates (CR), 39.6% (95% CI 32.4–47.3, p < 0.0001, I2 = 73.2%). ORRs were similar whether studies included or excluded rituximab-refractory, but CR appeared lower (28.6% vs. 42.9%). The number of prior lines of therapy did not affect response. Adding a third agent to R2 or len-anti-CD20 resulted in similar ORRs but significantly higher CR and 1- and 2-year progression-free survival appeared longer than that seen with R2. However, triplet regimens were associated with increased grade ≥3 toxicity. These findings reinforce the role of R2 in R/R FL in the modern treatment era. R2 at first relapse is effective across rituximab sensitivity profiles. Triplet combinations built on the R2 backbone improve efficacy but require careful patient selection and monitoring due to higher toxicity risks.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"35 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148769229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David L Murray, Jonathan Coker, Taxiarchis Kourelis, Angela Dispenzieri, Mindy Kohlhagen, Surendra Dasari, Maria Willrich
{"title":"Persistence of M-proteins detected by mass spectrometry.","authors":"David L Murray, Jonathan Coker, Taxiarchis Kourelis, Angela Dispenzieri, Mindy Kohlhagen, Surendra Dasari, Maria Willrich","doi":"10.1038/s41408-026-01610-y","DOIUrl":"https://doi.org/10.1038/s41408-026-01610-y","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13493880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexandra D Dreyfuss, Joachim Yahalom, Sridevi Rajeeve, Alexander M Lesokhin, Gunjan L Shah, Heather J Landau, Maximilian Merz, Michael Scordo, Andriy Derkach, David Nemirovsky, Harper Hubbeling, Gustav Cederquist, Zachary R Moore, Sergio A Giralt, Sham Mailankody, Saad Z Usmani, Brandon S Imber, Hamza Hashmi
{"title":"Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma.","authors":"Alexandra D Dreyfuss, Joachim Yahalom, Sridevi Rajeeve, Alexander M Lesokhin, Gunjan L Shah, Heather J Landau, Maximilian Merz, Michael Scordo, Andriy Derkach, David Nemirovsky, Harper Hubbeling, Gustav Cederquist, Zachary R Moore, Sergio A Giralt, Sham Mailankody, Saad Z Usmani, Brandon S Imber, Hamza Hashmi","doi":"10.1038/s41408-026-01607-7","DOIUrl":"https://doi.org/10.1038/s41408-026-01607-7","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13490575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mahnoor Fatima, Sudhesh Kumar, Momna Warraich, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek Mangaonkar, Antoine N Saliba, Mark R Litzow, William Hogan, Mithun V Shah, Mrinal M Patnaik, Animesh Pardanani, Talha Badar, James Foran, Jeanne Palmer, Cecilia Arana Yi, Ayalew Tefferi, Naseema Gangat
{"title":"Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia.","authors":"Mahnoor Fatima, Sudhesh Kumar, Momna Warraich, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek Mangaonkar, Antoine N Saliba, Mark R Litzow, William Hogan, Mithun V Shah, Mrinal M Patnaik, Animesh Pardanani, Talha Badar, James Foran, Jeanne Palmer, Cecilia Arana Yi, Ayalew Tefferi, Naseema Gangat","doi":"10.1038/s41408-026-01612-w","DOIUrl":"https://doi.org/10.1038/s41408-026-01612-w","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13483032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
